tadalafil has been researched along with aflatoxin b1 in 2 studies
| Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (aflatoxin b1) | Trials (aflatoxin b1) | Recent Studies (post-2010) (aflatoxin b1) |
|---|---|---|---|---|---|
| 1,742 | 392 | 1,089 | 4,532 | 49 | 1,715 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chhonker, SK; Koiri, RK; Rawat, D | 2 |
2 other study(ies) available for tadalafil and aflatoxin b1
| Article | Year |
|---|---|
Protective and therapeutic effects of sildenafil and tadalafil on aflatoxin B1-induced hepatocellular carcinoma.
Topics: Aflatoxin B1; Animals; Antioxidants; Carcinoma, Hepatocellular; Lipid Peroxidation; Liver Neoplasms, Experimental; Male; Phosphodiesterase 5 Inhibitors; Poisons; Rats; Sildenafil Citrate; Tadalafil; Vasodilator Agents | 2021 |
Repurposing PDE5 inhibitor tadalafil and sildenafil as anticancer agent against hepatocellular carcinoma via targeting key events of glucose metabolism and multidrug resistance.
Topics: Aflatoxin B1; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carbolines; Carcinoma, Hepatocellular; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Repositioning; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Glucose; Imidazoles; Liver Neoplasms; Neoplasm Proteins; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Rats; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2022 |